Investor FAQs

1.	How does the Company currently fund its research and development programs?
2.	When was StemCells incorporated, and in which state?
3.	How many people does StemCells employ?
4.	What is StemCells’ fiscal year end?
5.	On which exchange does StemCells trade and what is the symbol?
6.	When did StemCells become public?
7.	How many shares are outstanding?
8.	Does StemCells pay a dividend on its common stock?
9.	Does StemCells have a direct stock purchase plan?
10.	Who are StemCells' independent public accountants?
11.	Who is StemCells’ stock transfer agent?
12.	Who is StemCells’ legal counsel?
13.	How do I contact StemCells’ Investor Relations?
14.	How can I change my address or title on my StemCells stock certificate?

How does the Company currently fund its research and development programs?

We are focused on developing and commercializing cell-based therapeutics for diseases and disorders of the central nervous system. Our lead product, HuCNS-SC cells (purified human neural stem cells), is currently in clinical development for multiple indications. To date, our programs have been funded primarily by the sale of shares of common stock. As of December 31, 2011, we had $16.6 million in cash and cash equivalents and marketable securities

When was StemCells incorporated, and in which state?

The Company now known as StemCells, Inc. was incorporated in Delaware in August 1988, under the name Cellular Transplants, Inc. In February, 1992 the Company was renamed CytoTherapeutics and in April of that year the Company completed an initial public offering. In May 2000, the Company changed its name to StemCells, Inc., reflecting its decision to focus exclusively on stem cell technology, primarily for therapeutic use.

Q.	How many people does StemCells employ?
A.	As of December 31, 2011, we had 50 full-time employees.

Q.	What is StemCells’ fiscal year end?
A.	December 31.

Q.	On which exchange does StemCells trade and what is the symbol?
A.	Shares of StemCells common stock trade on the NASDAQ Global Market. The ticker symbol is STEM.

Q.	When did StemCells become public?
A.	The Company went public in 1992.

Q.	How many shares are outstanding?
A.	As of March 2, 2012, there were 23,924,881 shares of common stock issued and outstanding.

Q.	Does StemCells pay a dividend on its common stock?
A.	StemCells does not currently pay a dividend on its common stock and does not expect to pay any cash dividends in the foreseeable future.

Q.	Does StemCells have a direct stock purchase plan?
A.	No.

Q.	Who are StemCells' independent public accountants?
A.	Grant Thornton LLP is the Company's independent public accountant.

Q.	Who is StemCells’ stock transfer agent?
A.	Computer Share Investor Services P.O. Box 43023 Providence, RI 02940-3023 Phone: 781.575.2879 Fax: 617.360.6900 www.computershare.com

Q.	Who is StemCells’ legal counsel?
A.	Ken Stratton is StemCells' General Counsel. The Company's outside corporate counsel is Ropes and Gray of Boston and its patent counsel is Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, also of Boston.

Q.	How do I contact StemCells’ Investor Relations?
A.	You can contact Investor Relations by calling 510.456.4128 or via e-mail. Investor information can also be downloaded from our website at www.stemcellsinc.com.

Q.	How can I change my address or title on my StemCells stock certificate?
A.	All communications concerning stock transfer requirements, lost certificates, and changes of address or title should be directed to ComputerShare Investor Services, our stock transfer agent: Computer Share Investor Services P.O. Box 43023 Providence, RI 02940-3023 Phone: 781.575.2879 Fax: 617.360.6900 www.computershare.com

	Print Page
	E-mail Page
	RSS Feeds
	E-mail Alerts
	Financial Tear Sheet